CN105219714A - A kind of test kit for activating lung cancer specific immune response - Google Patents
A kind of test kit for activating lung cancer specific immune response Download PDFInfo
- Publication number
- CN105219714A CN105219714A CN201510684958.1A CN201510684958A CN105219714A CN 105219714 A CN105219714 A CN 105219714A CN 201510684958 A CN201510684958 A CN 201510684958A CN 105219714 A CN105219714 A CN 105219714A
- Authority
- CN
- China
- Prior art keywords
- cell
- test kit
- lung cancer
- supernatant
- seqidno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides a kind of test kit for activating lung cancer specific immune response, including RPMI-1640 substratum, cells and supernatant, GM-CSF, IL-4, INF γ and lung cancer specific antigens polypeptides in combination; Described cells and supernatant is NK cell and K562 co-culture of cells supernatant or T cell culture supernatant; Described lung cancer specific antigens polypeptides in combination is MAGE-A1-A2, MAGE-A1-A3, MAGE-A3-A2, MAGE-A4-A2/3, CEA-A2, CEA-A3, hTERT-A2, hTERT-A3, Survivin-A2 and Survivin-A3 antigenic peptide; Test kit of the present invention can activate the specific immune response of lung cancer patient in the mode that initiatively induction/passive induction phase combines efficiently.
Description
Technical field
The present invention relates to a kind of test kit strengthening antitumor immune, particularly relating to a kind of test kit for activating lung cancer specific immune response.
Background technology
It is the fastest that lung cancer is that M & M increases, to one of population health and the maximum malignant tumour of life threat.The many countries of immediate and mid-term all report that the M & M of lung cancer all obviously increases, and male lung cancer M & M all accounts for first of all malignant tumours, and women's sickness rate accounts for second, and mortality ratio accounts for second.
Since entering 21st century, molecular biology and immunologic rapid progress are that clinical cancer therapy provides new strategy.Identified the antigen of a large amount of tumor cell specifics by molecular biological means, and gone out it by the site of immunocyte identification by the means analysis of information biology, this is that the tumor-specific immunity of reconstruction patients reacts the possibility brought.But a series of clinical test results displays since last decade, the clinical effectiveness of the tumor vaccine based on tumour specific antigen peptide is disappointing, and one of them important reason is the defect of angtigen presentation process.
The DC cell of people's slow virus infections such as XiZhao makes the exogenous IL12 of its persistence high expression level, find that DC.IL12 cell can the generation of inducing antigen-specific CTL cell efficiently, DC.IL12 and tumor antigen peptide to be fed back in Mice Body can significance reduce tumor mass.The DC cell infecting unloaded virus can not effectively excite corresponding immune response, on the impact of the tumor size of mouse without significance after feedback.This research has pointed out the DC cell of high expression level IL12 tumor vaccine to be played to the importance of its anticancer clinical effect.
DC cell is a class cell in mammal body with HLA-II antigen, and its major function is picked-up, processing treatment and present antigen, activates or regulates adaptive immune response.Therefore T cell is activated and generates a type t helper cell (type1Thelper, Th1) of MHC-I class restricted CD8 positive cytotoxic T cells (CytotoxicTlymphocyte, CTL) and the restrictive CD4 positive of MHC-II class.One type polarization dendritic cell (Type1PolarizedDendriticcell, DC1) is a class subgroup of ripe DC cell, has strong immuno-stimulating ability.The important feature of DC1 cell is high expression level IL12p70 and immuno-stimulating costimulatory molecules, can activation antigen specific CD8+T cell is relevant with CD4+Th1 cell efficiently immune response.RobbieB.Mailliard etc. confirm that the ability of the external evoked melanoma-associated antigen of DC1 specific CTL cell can reach more than 40 times of normal ripe DC cell.The people such as AdrianaTLarregina also find DC1 cell induction B16 melanoma-associated antigen specific C D4+ helper T cell, and promote that CD4+ helper T cell is to the infiltration of tumor tissues.Therefore, the DC1 cell loading tumour specific antigen peptide of high expression level IL12 can provide a kind of strategy for the oncotherapy curative effect based on enhancement antigen peptide, but also do not have in prior art can be corresponding, ripe and be applicable to activate the test kit of lung cancer patient specific immune response.
Summary of the invention
The present invention solves the aforementioned problems in the prior to propose the clinical treatment of a kind of test kit for lung cancer.The DC cell that external evoked tumour patient is autologous, obtains the product of enrichment DC1 cell; DC1 cell loading tumour-specific peptide section combines, and may be used for the induction of the cytotoxic T cell of the specific for tumour antigen in external or body.
In order to solve the problems of the technologies described above, technical measures provided by the present invention are:
The invention provides a kind of test kit for activating lung cancer specific immune response, including RPMI-1640 substratum, cells and supernatant, GM-CSF, IL-4, INF γ and lung cancer specific antigens polypeptides in combination; Wherein, described cells and supernatant is NK cell and K562 co-culture of cells supernatant or T cell culture supernatant; Described lung cancer specific antigens polypeptides in combination comprises MAGE-A1-A2, MAGE-A1-A3, MAGE-A3-A2, MAGE-A4-A2/3, CEA-A2, CEA-A3, hTERT-A2, hTERT-A3, Survivin-A2 and Survivin-A3 antigenic peptide, its peptide sequence is respectively as SEQIDNo.1, SEQIDNo.2, SEQIDNo.3, SEQIDNo.4, SEQIDNo.5, SEQIDNo.6, shown in SEQIDNo.7, SEQIDNo.8, SEQIDNo.9 and SEQIDNo.10.
In order to optimize technique scheme further, the technical measures that the present invention takes also comprise:
Preferably, NK cell and K562 co-culture of cells supernatant by K562 cell and NK cell are added IFN α in 1:2 to 1:10 ratio Dual culture, 24 h before harvest substratum supernatants and obtaining.
Preferably, in the preparation process of described T cell culture supernatant, first separating periphery blood monocytic cell, lymphocyte separation medium sub-argument mononuclearcell, after going out CD8+T cell with CD8 magnetic bead sorting, be seeded in substratum, add CD3CD28Beads, add equivalent substratum after 24h, after 48h, collect T cell culture supernatant.
Preferably, utilize test kit to activate the reaction of lung cancer patient tumor-specific immunity to comprise the following steps:
Step one, be separated the monocyte in patient's peripheral blood, after the of short duration adherent culture of cell, remove suspension cell, add inductor GM-CSF and IL-4 and cultivate two days, cultivate the 3rd day, within the 5th day, change the substratum of half amount, and add lung cancer specific antigens polypeptides in combination, obtain the ripe DC cell that load has lung cancer specific antigens polypeptides in combination;
Step 2, cultivates induction further two days by ripe DC cell INF γ obtained in described step one and described NK cell and K562 co-culture of cells supernatant, makes described ripe DC cytodifferentiation be DC1 cell;
Step 3, the DC1 cell utilizing step 2 to obtain carries out initiatively induction and/or external passive induction in body.
Preferably, described NK cell derived is in Human Umbilical Cord's blood.
Preferably, described T cell culture supernatant is for utilizing autologous or allogeneic T cells acquisition.
Preferably, initiatively Induction Process feeds back in patient body for the DC1 cell described step 2 obtained in the body in described step 3.
Preferably, the external passive Induction Process in described step 3 is the DC1 cell that described step 2 obtained and T cell mixed culture, and the specific antigens of load lung cancer again polypeptide, then collecting cell, feeds back in patient body.
Preferably, test kit can also comprise GGT551 substratum, DMEM/F12 substratum or DMEM substratum.
The present invention adopts technique scheme, and compared with prior art, technique effect of the present invention is embodied in the following aspects:
First, the invention provides one group of specific antigens polypeptides in combination for lung cancer immunotherapy, this combination contains the peptide section of the specific expressed antigen of multiple lung carcinoma cell.These peptide sections include the sequence area that HLA-A2 and A3 presents, and cover the lung carcinoma cell specific antigens reported of more than 80%.Therefore, we provide a kind of new lung cancer specific antigens polypeptides in combination, be conducive to activating the acquired immune response for tumour cell suffering from lung cancer patient.
Secondly, present invention also offers one and utilize test kit of the present invention, the ripe DC1 cell of external preparation, for the method for load lung carcinoma cell specific antigens combination.Compared with conventional induction scheme, the DC cell content significance having ripe phenotype in the product prepared by test kit of the present invention is utilized to improve (as surface antigen high expression levels such as CD80, CD86, CD40L); After sCD40L stimulates, DC1 cell IL12P70 expression amount is much higher than the expression amount that general scheme prepares cell.As can be seen here, the invention provides more effective ripe DC1 cell and prepare scheme, gained cellular products may be used for the load of lung carcinoma cell specific antigens.
Finally, the invention provides a kind of clinical application protocol of the DC1 Loading peptides for lung cancer therapy.After DC1 cell loading tumour specific antigen, part cell is fed back in patient body, another part is used for the inducing cytotoxic T cell (CTL) of Vitro Tumor antigen-specific, by in body/external, the mode that initiatively induction/passive induction phase combines activates the specific immune response of lung cancer patient.
Accompanying drawing explanation
Compared with the ripe DC cell that Fig. 1 is prepared for DC1 cell and the conventional scheme utilizing test kit of the present invention (cells and supernatant is NK cell and K562 co-culture of cells supernatant) and prepare, CCR7, CD70, HLA-DR, the marker expression amount situation that the DC cells such as CD83, CD86 are relevant to immuno-stimulating;
Compared with Fig. 2 contrast DC cell that to be the DC1 cell T cell culture supernatant of 40% ratio (10% with) prepared of test kit of the present invention (cells and supernatant is T cell culture supernatant) prepare with conventional scheme, CD11C, CD70, HLA-DR, the marker expression amount situation that the DC cells such as CD83, CD86 are relevant to immuno-stimulating;
Fig. 3 is after sCD40L activates, the contrast of the IL-12 secreted by DC1 cell prepared by test kit of the present invention (cells and supernatant is NK cell and K562 co-culture of cells supernatant) and ripe DC emiocytosis amount prepared by conventional scheme;
Fig. 4 is after sCD40L activates, the contrast of the IL-12 secreted by DC1 cell (the T cell culture supernatant of 10% and 40% ratio) prepared by test kit of the present invention (cells and supernatant is T cell culture supernatant) and ripe DC emiocytosis amount prepared by conventional scheme;
After Fig. 5 is the DC1 cell induction T cell prepared of test kit of the present invention (cells and supernatant is NK cell and K562 co-culture of cells supernatant), the contrast of DC cell induction prepared by IFN γ secretion level and common approach in ELIspot test;
After Fig. 6 is DC1 cell (the T cell supernatant of the 10% and 40% ratio) inducing T cell prepared of test kit of the present invention (cells and supernatant is T cell culture supernatant), the contrast of DC cell induction prepared by IFN γ secretion level and common approach in ELIspot test.
Embodiment
The invention provides a kind of test kit for activating lung cancer specific immune response, including RPMI-1640 substratum, cells and supernatant, GM-CSF, IL-4, INF γ and lung cancer specific antigens polypeptides in combination; Wherein, described cells and supernatant is NK cell and K562 co-culture of cells supernatant or T cell culture supernatant; Described lung cancer specific antigens polypeptides in combination comprises MAGE-A1-A2, MAGE-A1-A3, MAGE-A3-A2, MAGE-A4-A2/3, CEA-A2, CEA-A3, hTERT-A2, hTERT-A3, Survivin-A2 and Survivin-A3 antigenic peptide, its peptide sequence is respectively as SEQIDNo.1, SEQIDNo.2, SEQIDNo.3, SEQIDNo.4, SEQIDNo.5, SEQIDNo.6, shown in SEQIDNo.7, SEQIDNo.8, SEQIDNo.9 and SEQIDNo.10.
Carry out detailed and concrete introduction below by specific embodiment to the present invention, to make better to understand the present invention, but following embodiment does not limit the scope of the invention.
Embodiment one (cells and supernatant is T cell culture supernatant)
When utilizing test kit of the present invention to activate lung cancer patient specific immune response, first carry out the preparation (type1polarizeddendriticcell, DC1) of a type polarization dendritic cell in adult peripheral blood source.Peripheral blood mononuclear cell is separated with reference to the method according to (GeneTher.200310 (3)) such as Jonuleit.First with by Ficoll-Hypaque density gradient centrifugation separating peripheral blood mononuclear cells, and blood plasma is collected for follow-up cultivation.By density 3.0 × 10
6/ ml, is seeded to cell in T75 culturing bottle, and adds 10% blood plasma in GGT551 substratum, be placed in 37.0 DEG C, saturated humidity, 5%CO
2cultivate in environment.After cultivating 3h, wash away the lymphocyte of suspension, add the DMEM/F12 substratum containing GM-CSF and IL-41000IU/ml and 10% blood plasma.Attached cell cultivates the 3rd day, within the 5th day, changes the substratum of half amount.Cultivate the 5th day, change containing 5% plasma medium and add T cell supernatant 10%, and adding IFN α according to final concentration, cultivate the poly-I:C that 20 hours add 20ug/ml afterwards again.As shown in Figure 2, through the induction of 6 days, prepare the phenotype that product shows obvious DC cell, the mark relevant to immuno-stimulating such as Flow cytometry result display CD83, CD86 etc. reaches more than 95%, illustrates that to prepare DC cell purity in product high.Also can be found out by Fig. 4, DC1 cell is after sCD40L stimulates, and high expression level IL12, the IL12 amount of the DC cell expressing prepared by test kit of the present invention is approximately 10 times (10%T-DC) of conventional scheme.In detection experiment, within the 5th day, add 10% or the induction of 40%T cell conditioned medium, the DC1 cell of acquisition through sCD40L activate after with T cell Dual culture.ELIspot test (Fig. 6) shows the quantity of quantity higher than common DC cell induction that IFN γ expresses positive T cell.
DC1 cell cultures was to the 6th day, by centrifugal for each tumor antigen peptide section pulvis in test kit rear (300g, 10min), often prop up and be dissolved in (each peptide 2ug/ml) in 200ulDMEM/F12 substratum respectively, join after abundant mixing in DC1, hatch 2h.The DC1 cell collected is divided into two parts, every part at least 10
6individual cell, may be used for directly mixing with peptide feeding back in patient body, or for external evoked CTL cell.During DC1 cells in vitro induced tumor Peptide-specific CTL cell, as aforesaid method separating periphery blood monocytic cell, of short duration cultivation in adherent culture ware, the cell that separation can be adherent.Suspension cell is by density 3.0 × 10
6/ ml inoculation culture.Multiple proportions adds RPMI1640 substratum every three days.To cultivating the 5th day and the 6th day, adding respectively to add and activating each 1ml of reagent IFN-γ, CD3 and IL1-α mixed solution.By the antigen peptide load DC1 of acquisition and T cell mixed culture.Multiple proportions adds RPMI1640 substratum every three days.Mixed culture starts latter 4th day, the specific antigens of load lung cancer again peptide.By centrifugal for the tumor antigen peptide pulvis in test kit rear (300g, 10min), often pipe adds the GGT551 substratum of 1ml respectively, after fully dissolving mixing, adds in culture system.Afterwards, continue to be cultured to feedback, T cell Time in Vitro should more than 18 days.
The clinical application of the DC1 cell that test kit of the present invention (cells and supernatant is T cell culture supernatant) is induced:
The method of application foregoing description, the present invention is directed to lung cancer patient to have employed DC1 mediated immunity therapy and carry out methods for the treatment of and be summarized as follows: met patient's (III or IV level) of inclusion criteria before carrying out chemotherapy, get peripheral blood 150ml, be prepared the CTL cell of DC1 and specific for tumour antigen by above-mentioned method.
6th day 5-10 × 10 at the lymph node injection antigen load of patient
6individual DC1 cell (being resuspended in 1ml physiological saline), cultivate the 16,17,18 day every day collected 10
9individual DC and T cell Dual culture product, after resuspended in physiological saline, venous re-transfusion.Completed 9 examples at present, just in follow-up observation, not yet find obvious complication, proved method safety is reliable.
Embodiment two (cells and supernatant is NK cell and K562 co-culture of cells supernatant)
Peripheral blood mononuclear cell is separated with reference to the method according to (GeneTher.200310 (3)) such as Jonuleit.First with by Ficoll-Hypaque density gradient centrifugation separating peripheral blood mononuclear cells, and blood plasma is collected for follow-up cultivation.Add IL-2 (2000U/ml) and IL15 (2ng/ml).Within every two to three days, multiple proportions adds substratum, and equivalent SF.Collected to the 12 day.After having induced, NK cell presses 1-3 × 10
6/ ml is seeded in substratum RPMI1640, adds IFNa (1000UI/ml) and with 0.5-1.5 × 10
5/ ml density inoculation K562 cell (can be replaced K562-NK cell) mixed culture, collects the substratum supernatant activated in 24-48 hours period, and after filtration ,-80 degree are frozen or be directly used in the preparation of DC1 cell.Peripheral blood mononuclear cell is by density 3.0 × 10
6/ ml, is seeded to cell in T75 culturing bottle, and containing adding 10% blood plasma in 1000U/mlIL-2 amplification culture medium, be placed in 37.0 DEG C, saturated humidity, 5%CO
2cultivate in environment.After cultivating 3h, wash away the lymphocyte of suspension, add the substratum containing GM-CSF and IL-41000U/ml and 10% blood plasma.Attached cell cultivates the 3rd day, within the 5th day, changes the substratum of half amount.Cultivate the 6th day, change containing 5% plasma medium and add NK cell conditioned medium 10%, and adding IFN γ according to final concentration 1000UI/ml, cultivate the poly-I:C that 20 hours add 20ug/ml afterwards again.Be cultured to the 7th day collecting cell and be DC1 cell.DC1s cell cultures was to the 6th day, by centrifugal for each lung cancer antigen polypeptide section pulvis in CTL-TP test kit rear (300g, 10min), often prop up and be dissolved in (each peptide 2ug/ml) in 200ul substratum respectively, join after abundant mixing in DC1, hatch 2h.The DC1 cell collected is divided into two parts, every part at least 10
6individual cell, may be used for directly mixing with peptide feeding back in patient body, or for external evoked CTL cell.
As aforesaid method separating periphery blood monocytic cell, of short duration cultivation in adherent culture ware, the cell that separation can be adherent.Suspension cell is by density 3.0 × 10
6/ ml inoculation culture.Multiple proportions adds the amplification culture medium containing 1000U/mlIL-2 every three days.Adding IFN-γ to cultivating the 5th day, within the 6th day, adding IL-1 α and CD3.
By the antigen peptide load DC1 of above-mentioned acquisition and T cell mixed culture.Multiple proportions adds the amplification culture medium containing 1000U/ml every three days.Mixed culture starts latter 4th day, the specific antigens of load lung cancer again peptide.By centrifugal for the tumor antigen peptide pulvis in CTL-TP test kit rear (300g, 10min), often pipe adds the substratum of 1ml respectively, after fully dissolving mixing, adds in culture system.Afterwards, continue to be cultured to feedback, T cell Time in Vitro should more than 20 days.
As shown in Figure 1, through induction, compared with ripe DC cell prepared by the DC1 cell prepared of test kit of the present invention and conventional scheme, multiple surface markers of the mark that the DC cells such as CCR7, CD70, HLA-DR, CD83, CD86 are relevant to immuno-stimulating become the positives.Also can be found out by Fig. 3, the cellular products IL12p70 expression amount that the present invention prepares and obtains is much higher than scheme conventional at present, and the IL-12 secreted by DC1 cell of the present invention's induction is almost 10 times of ripe DC emiocytosis amount prepared by conventional scheme.In detection experiment, external evoked experiment display is after DC1 induction prepared by this test kit, and the T cell of activation and IFN γ express positive T cell significance and raise (Fig. 5).
The clinical application of the DC1 cell that test kit of the present invention (cells and supernatant is T cell culture supernatant) is induced:
The method of application foregoing description, the present invention is directed to lung cancer patient to have employed DC1 mediated immunity therapy and carry out methods for the treatment of and be summarized as follows: met patient's (III or IV level) of inclusion criteria before carrying out chemotherapy, get peripheral blood 150ml, be prepared the CTL cell of DC1 and specific for tumour antigen by above-mentioned method.
7th day 5-10 × 10 at the lymph node injection antigen load of patient
6individual DC1 cell (being resuspended in 1ml physiological saline), cultivate the 16,17,18 day every day collected 10
9individual DC and T cell Dual culture product, after resuspended in physiological saline, venous re-transfusion.Completed 10 examples at present, just in follow-up observation, not yet find obvious complication, proved method safety is reliable.
A kind of test kit for activating lung cancer specific immune response of the present invention, has the following advantages relative to prior art tool:
First, the invention provides one group of specific antigens polypeptides in combination for lung cancer immunotherapy, this combination contains the peptide section of the specific expressed antigen of multiple lung carcinoma cell.These peptide sections include the sequence area that HLA-A2 and A3 presents, and cover the lung carcinoma cell specific antigens reported of more than 80%.Therefore, we provide a kind of new lung cancer specific antigens polypeptides in combination, be conducive to activating the acquired immune response for tumour cell suffering from lung cancer patient.
Secondly, present invention also offers one and utilize kit box of the present invention to prepare ripe DC1 cell outward, for the method for load lung carcinoma cell specific antigens combination.Compared with conventional induction scheme, the DC cell content significance having ripe phenotype in the product prepared by test kit of the present invention is utilized to improve (as surface antigen high expression levels such as CD80, CD86, CD40L); After sCD40L stimulates, DC1 cell IL12P70 expression amount is much higher than the expression amount that general scheme prepares cell.As can be seen here, the invention provides more effective ripe DC1 cell and prepare scheme, gained cellular products may be used for the load of lung carcinoma cell specific antigens.
Finally, the invention provides a kind of clinical application protocol of the DC1 Loading peptides for lung cancer therapy.After DC1 cell loading lung cancer specific antigens, part cell is fed back in patient body, another part is used for the inducing cytotoxic T cell (CTL) of Vitro Tumor antigen-specific, by in body/external, the mode that initiatively induction/passive induction phase combines activates the specific immune response of patients with lung cancer.
Be described in detail specific embodiments of the invention above, but it is just as example, the present invention is not restricted to specific embodiment described above.To those skilled in the art, any equivalent modifications that the present invention is carried out and substituting also all among category of the present invention.Therefore, equalization conversion done without departing from the spirit and scope of the invention and amendment, all should contain within the scope of the invention.
Claims (9)
1. for activating a test kit for lung cancer specific immune response, it is characterized in that, including RPMI-1640 substratum, cells and supernatant, GM-CSF, IL-4, INF γ and lung cancer specific antigens polypeptides in combination; Wherein, described cells and supernatant is NK cell and K562 co-culture of cells supernatant or T cell culture supernatant; Described lung cancer specific antigens polypeptides in combination is the polypeptides in combination of sequence as SEQIDNo.1, SEQIDNo.2, SEQIDNo.3, SEQIDNo.4, SEQIDNo.5, SEQIDNo.6, SEQIDNo.7, SEQIDNo.8, SEQIDNo.9 and SEQIDNo.10.
2. test kit according to claim 1, is characterized in that, described NK cell and K562 co-culture of cells supernatant by K562 cell and NK cell are added IFN α in 1:2 to 1:10 ratio Dual culture, 24 h before harvest substratum supernatants and obtaining.
3. test kit according to claim 1, it is characterized in that, in the preparation process of described T cell culture supernatant, first separating periphery blood monocytic cell, lymphocyte separation medium sub-argument mononuclearcell, after going out CD8+T cell with CD8 magnetic bead sorting, be seeded in substratum, add CD3CD28Beads, after 24h, add equivalent substratum, after 48h, collect T cell culture supernatant.
4. test kit according to claim 1, is characterized in that, utilizes test kit to activate the reaction of lung cancer patient tumor-specific immunity and comprises the following steps:
Step one, be separated the monocyte in patient's peripheral blood, after the of short duration adherent culture of cell, remove suspension cell, add inductor GM-CSF and IL-4 and cultivate two days, cultivate the 3rd day, within the 5th day, change the substratum of half amount, and add lung cancer specific antigens polypeptides in combination, obtain the ripe DC cell that load has lung cancer specific antigens polypeptides in combination;
Step 2, cultivates induction further two days by ripe DC cell INF γ obtained in described step one and described NK cell and K562 co-culture of cells supernatant, makes described ripe DC cytodifferentiation be DC1 cell;
Step 3, the DC1 cell utilizing step 2 to obtain carries out initiatively induction and/or external passive induction in body.
5. test kit according to claim 1 and 2, is characterized in that, described NK cell derived is in Human Umbilical Cord's blood.
6. the test kit according to claim 1 or 3, is characterized in that, described T cell culture supernatant is for utilizing autologous or allogeneic T cells acquisition.
7. test kit according to claim 4, is characterized in that, initiatively Induction Process feeds back in patient body for the DC1 cell described step 2 obtained in the body in described step 3.
8. test kit according to claim 4, it is characterized in that, the external passive Induction Process in described step 3 is the DC1 cell that described step 2 obtained and T cell mixed culture, and the specific antigens of load lung cancer again polypeptide, then collecting cell, feeds back in patient body.
9. test kit according to claim 1, is characterized in that, also includes GGT551 substratum, DMEM/F12 substratum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510684958.1A CN105219714A (en) | 2015-10-20 | 2015-10-20 | A kind of test kit for activating lung cancer specific immune response |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510684958.1A CN105219714A (en) | 2015-10-20 | 2015-10-20 | A kind of test kit for activating lung cancer specific immune response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105219714A true CN105219714A (en) | 2016-01-06 |
Family
ID=54988985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510684958.1A Pending CN105219714A (en) | 2015-10-20 | 2015-10-20 | A kind of test kit for activating lung cancer specific immune response |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105219714A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019515650A (en) * | 2016-03-16 | 2019-06-13 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Peptides and peptide combinations for use in immunotherapy against non-small cell lung cancer and other cancers |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1541113A (en) * | 2001-04-27 | 2004-10-27 | �Ƹ��� | Maturation of antigen-presenting cells using activated T cells |
| CN101896601A (en) * | 2007-12-12 | 2010-11-24 | 特里梅德生物有限责任公司 | Method for producing dendritic cells |
| CN102356154A (en) * | 2008-10-24 | 2012-02-15 | 株式会社美迪赛 | Method for efficiently proliferating and differentiating natural killer cells from umbilical cord blood |
-
2015
- 2015-10-20 CN CN201510684958.1A patent/CN105219714A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1541113A (en) * | 2001-04-27 | 2004-10-27 | �Ƹ��� | Maturation of antigen-presenting cells using activated T cells |
| CN101896601A (en) * | 2007-12-12 | 2010-11-24 | 特里梅德生物有限责任公司 | Method for producing dendritic cells |
| CN102356154A (en) * | 2008-10-24 | 2012-02-15 | 株式会社美迪赛 | Method for efficiently proliferating and differentiating natural killer cells from umbilical cord blood |
Non-Patent Citations (2)
| Title |
|---|
| JEFFREY L. WONG ET AL.: "Helper Activity of NK Cells during the Dendritic Cell-mediated Induction of Melanoma-specific Cytotoxic T Cells", 《J IMMUNOTHER》 * |
| PAWEL KALINSKI ET AL.: "Helper role of NK cells during the induction of anticancer responses by dendritic cells", 《MOLECULAR IMMUNOLOGY》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019515650A (en) * | 2016-03-16 | 2019-06-13 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Peptides and peptide combinations for use in immunotherapy against non-small cell lung cancer and other cancers |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Son et al. | A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells | |
| CN104321425B (en) | Method for inducing and expanding the natural killer cells from peripheral blood mononuclear cells | |
| CN103756963B (en) | A kind of method of amplification in vitro NK cell | |
| US9211321B2 (en) | Method for proliferation of antigen-specific T cells | |
| CN105176927A (en) | Preparation method of cytotoxicity-enhanced efficient target killing NK/CIK (Natural Killer)/( Cytokine Induced Killer) cells | |
| CN106581668B (en) | Antigen epitope peptide composition and application thereof | |
| CN110564683A (en) | Method for co-culture induced amplification of gamma delta T cells and NK cells | |
| CN102719402B (en) | Preparation method of HLA-A0201-restricted anti-HPV (human papillomavirus) antigen-specific CTL | |
| CN112980787B (en) | Immune cell preparation for specifically killing tumor cells and preparation method and application thereof | |
| CN105838674A (en) | Method for inducing in-vitro expansion of CD8<+> regulatory T cells by immunosuppressants | |
| CN109957543A (en) | Utilize the method for Cord blood massive amplification Cord Blood Natural Killer Cells: Impact | |
| Delirezh et al. | Generation of mature monocyte-derived dendritic cells in the presence of heparin and monocyte conditioned medium: phenotypic and functional comparison | |
| CN103372204A (en) | External xenoliths vaccine combined dendritic cell cytokine induced killer (DC-CIK) new technology for cancer therapy | |
| CN105219727A (en) | A kind of test kit for activating colorectal cancer specific immune response | |
| CN105219728A (en) | A kind of for activating the immunoreactive test kit of Breast Cancer-Specific | |
| CN105219714A (en) | A kind of test kit for activating lung cancer specific immune response | |
| Cao et al. | Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma | |
| CN105219723A (en) | A kind of test kit for activating cancer of the stomach specific immune response | |
| CN105219715A (en) | A kind of test kit for activating esophageal carcinoma specific immune response | |
| CN105219717A (en) | An a kind of type polarization dendritic cell and induction method thereof and application | |
| TW201402137A (en) | Application of cytotoxic dendritic cells for manufacturing medication and comprising pharmaceutical composition | |
| CN105219719A (en) | A kind of test kit for activating ovarian cancer specific immune response | |
| CN105219724A (en) | A kind of test kit for activating melanoma specific immune response | |
| CN105219720A (en) | A kind of for activating the immunoreactive test kit of liver cancer-specific | |
| CN105219721A (en) | A kind of for activating the immunoreactive test kit of Pancreatic Cancer-Specific |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160106 |
|
| RJ01 | Rejection of invention patent application after publication |